Erdafitinib丨CAS 1346242-81-6

Erdafitinib丨CAS 1346242-81-6
Product Introduction:
CAS No.: 1346242-81-6
Product Name: Erdafitinib
Molecular Formula: C25H30N6O2
Molecular Weight: 446.5
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of erdafitinib丨cas 1346242-81-6 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Major Supplier of Erdafitinib丨CAS 1346242-81-6

 

Erdafitinib, also known as JNJ-42756493, is an orally bioavailable, small-molecule tyrosine kinase inhibitor belonging to the fibroblast growth factor receptor (FGFR) inhibitor class. It contains a quinoxaline core, a methylpyrazole group, and a dimethoxyphenyl substituent. By inhibiting FGFR1, FGFR2, FGFR3, and FGFR4 signaling, it is an important targeted anticancer compound used in pharmaceutical development and oncology research.

 
 
 
 
 
 

 

 

Chemical Identifiers

 

InChI 1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3
InChI Key OLAHOMJCDNXHFI-UHFFFAOYSA-N
Smiles CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC
EC No.

807-395-6

MDL No. MFCD28502040
PubChem CID 67462786

 

 

 

Applications

 

Targeted Cancer Therapy

Used as an active pharmaceutical ingredient in the treatment of locally advanced or metastatic urothelial carcinoma in patients with susceptible FGFR2 or FGFR3 genetic alterations, according to approved prescribing indications.

 

FGFR Signaling Research

Serves as a selective inhibitor for investigating FGFR1–4 activity and their roles in cell growth, differentiation, and intracellular signaling pathways.

 
 

 

Anticancer Drug Discovery

Used in preclinical studies to evaluate the effects of FGFR inhibition on tumor-cell proliferation, survival, and tumor growth in cellular and animal models.

Biomarker-Guided Oncology Research

Supports research into FGFR genetic alterations, including mutations, amplifications, and gene fusions, helping investigate the relationship between molecular biomarkers and responses to targeted therapies.

 
 
 
 
 
 
 
 

 

 

 

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us